Statements (37)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiretroviral therapy |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2003
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AE07
|
| gptkbp:CASNumber |
226700-79-4
|
| gptkbp:chemicalFormula |
C25H36N3O9PS
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:eliminationHalfLife |
7.7 hours
|
| gptkbp:genericName |
fosamprenavir
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lexiva
|
| gptkbp:interactsWith |
gptkb:ritonavir
statins antacids |
| gptkbp:KEGGID |
D04097
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:ViiV_Healthcare
GlaxoSmithKline |
| gptkbp:metabolism |
gptkb:amprenavir
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:PubChem_CID |
CHEMBL1201192
65016 DB01319 58536 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea headache rash |
| gptkbp:synonym |
GW433908
|
| gptkbp:UNII |
GSL8U4ISV9
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Fosamprenavir
|
| gptkbp:bfsLayer |
7
|